Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 15,026 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vascular Clear all

Conditions: Carotid Artery Diseases, Atherosclerosis
Interventions: Valsartan, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: lenalidomide (Revlimid®), Cyclophosphamide, Prednisone; Drug
Lead sponsor: Attaya Suvannasankha; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Stroke
Interventions: CARE-CITE Education Program, Traditional Education, Constraint-Induced Movement Therapy (CIMT); Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pulmonary Hypertension
Interventions: UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more

Conditions: Chronic Kidney Disease, Endstage Renal Disease
Interventions: Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG); Procedure
Lead sponsor: Columbia University; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Visual Field Defect, Stroke, Hemianopia, Quadrantanopia, Cortical Blindness, Brain Tumor, Traumatic Brain Injury, Visual Field Defect, Peripheral
Interventions: transcranial random noise stimulation (tRNS), Sham Stimulation, Perceptual learning-based training; Device · Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Coronary Artery Disease
Interventions: ABT NG DES 48 EECSS; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 18
States / cities: Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 13 more

Conditions: Raynaud Disease, Raynaud Phenomenon, Raynaud Syndrome
Interventions: Blue Light Therapy, Sham Light Therapy; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stroke, Cerebral Ischemia, Brain Infarction
Interventions: Ancrod (Viprinex), Placebo; Drug
Lead sponsor: Neurobiological Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 58
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Loma Linda, California + 48 more

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: Ambrisentan, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Multiple Myeloma
Interventions: Selinexor, Placebo (for selinexor), carfilzomib, Dexamethasone; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: West Hollywood, California • Cary, North Carolina

Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: dalteparin, lenalidomide, dexamethasone, laboratory biomarker analysis; Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glioblastoma Multiforme
Interventions: Bevacizumab; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Stroke
Interventions: Reactive Perturbations, Proactive Perturbations; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Coronary Artery Disease
Interventions: Prasugrel, Ticagrelor; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Pre-Eclampsia; Complicating Pregnancy, Gestational Hypertension
Interventions: Video, Text Reminder, Blood pressure threshold; Other
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Diabetic Macular Edema
Interventions: NOVA63035 "Corticosteroid"; Drug
Lead sponsor: Santen SAS; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Kawasaki Disease
Interventions: Atorvastatin and anakinra; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 1 Year to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Myocardial Infarction
Interventions: Dapansutrile, Placebo; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 25 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Stroke
Interventions: Telemedicine, Clinic; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Dementia, Alzheimer Disease, Dementia, Vascular, Dementia, Mixed, Dementia of Alzheimer Type
Interventions: SAFE at Home; Behavioral
Lead sponsor: Hopeful Aging; Industry
Eligibility: 60 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Winchester, Massachusetts

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf); Biological
Lead sponsor: Shire; Industry
Eligibility: 1 Year and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 48
States / cities: Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more

Conditions: HIV Infections
Interventions: Pravastatin, Gemfibrozil, Rosiglitazone; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy, Diabetes Mellitus, Type 2, Glaucoma
Interventions: Behavioral Activation, Supportive Therapy; Behavioral
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Effect of Valsartan on Carotid Artery Disease

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

Evaluation of a CarePartner-Integrated Telehealth Rehabilitation Program for Persons With Stroke

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis

Vision Improvement Through Behavioral Rehabilitation And Neuroplasticity Training

Abbott Next Generation Drug Eluting Stent 48mm Study

Phototherapy For Treatment Of Raynaud's Phenomenon

Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)

Post-stroke Perturbation Training

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education

Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI

Stroke Therapy, Education, Prevention: Telemedicine Outpatient Initiative Trial

All About Me: An Intervention to Ease the Transition to Long Term Care

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Endothelial Dysfunction as a Risk Factor in HIV Study

Confronting Unequal Eye Care in Pennsylvania